Business Context and Reporting Period
This Form 8-K Current Report from Alnylam Pharmaceuticals, Inc. covers events occurring between January 20, 2015, and January 26, 2015. The filing primarily details the execution of a public equity offering and related private placements to maintain shareholder ownership percentages.
Key Financial Metrics
- Public Offering Proceeds: The Company sold 4,736,842 shares of common stock at $95.00 per share. Net proceeds are expected to be approximately $431.6 million after underwriting discounts and estimated expenses.
- Private Placement Proceeds (Genzyme): Genzyme Corporation purchased a total of 843,699 shares in two separate transactions:
- 196,251 shares at $93.17 per share for approximately $18.3 million.
- 647,448 shares at $95.00 per share for approximately $61.5 million.
- Total Capital Raised: Approximately $511.4 million combined from the public offering and Genzyme private placements.
- Underwriting Option: Underwriters hold a 30-day option to purchase up to an additional 710,526 shares.
Material Changes
The primary material change is the significant increase in cash liquidity resulting from the equity financing activities. Additionally, Genzyme Corporation exercised rights under a 2014 Investor Agreement to maintain its ownership stake at approximately 12% of the Company's outstanding common stock following the dilution from the public offering.
Outlook, Risks, and Management Commentary
The filing does not provide specific forward-looking guidance, risk factors, or management commentary regarding operational performance. The transaction was executed pursuant to an automatically effective shelf registration statement filed in December 2012. The private placements to Genzyme were exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
Investor Verification Checklist
- Verify the final closing date and confirmation of net proceeds received (reported as January 26, 2015).
- Confirm whether the underwriters exercised the option to purchase the additional 710,526 shares.
- Review the updated capitalization table to confirm Genzyme's post-transaction ownership percentage.
- Examine the use of proceeds disclosed in the associated prospectus supplement (Exhibit 99.1).